Trading Statement

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to issue the following trading statement for H1 2025.

GenIP continues to build momentum. The Company's cash balance increased to $1,077k at 30 June 2025 (31 December 2024: $972k) driven by record orders and effective cost controls. In the first half of 2025, we secured $488k in new orders, including material contract wins in Asia, expanding our catchment market, which have positively impacted working capital.

Total orders received since GenIP's AIM listing in October 2024 stand at $981k, and the outstanding order book totals $813k, providing visibility of revenue generation in H2 2025.

The business was acquired by GenIP in June 2024 and the strategic ramp-up of expenditure and marketing took place following the October 2024 IPO, so there is no direct comparability between H1 2025 and FY2024 revenue performance.

Nevertheless, H1 2025 revenue is expected to reach approximately $128k, modestly ahead of PE2024's total ($123k). This uplift reflects the timing of several significant orders secured in the first half, which are scheduled for delivery and revenue recognition in H2. These early wins underscore the commercial progress made since IPO and position the Company for continued growth in the second half of the year.

The Company continues to maintain a strong pipeline of new business as it delivers on its global growth strategy. During the period, GenIP has entered new markets including Brazil, Chile and the UK academic market. In addition to the continued growth of existing products, the Company looks forward to enhancing revenue generation by launching new products currently in development phases. GenIP's Invention Evaluator services accounted for the majority of first half revenue and orders, with Vortechs expected to make a more significant contribution in the second half.

Investment in technology development continues with delivery expected at the beginning of Q3, serving as a growth enabler.

Outlook

GenIP is in a robust position with clear revenue visibility going into the second half of 2025. Given the typical time lag between order receipt and revenue recognition, we expect an uplift in revenue in H2 2025. Demand for GenIP's Generative AI analytics services is strong, and the Company is laser-focused on growing its order book while continuing to maintain a robust balance sheet.

Melissa Cruz, CEO of GenIP, commented:

"We are extremely encouraged by the strong commercial traction we've achieved in such a short period since our IPO. The size and quality of our order book reflect the value our services bring to clients worldwide. We're seeing increasing demand for our solutions as institutions seek faster, data-driven ways to unlock the value of their innovations. With a strong balance sheet and a growing pipeline of opportunities, we are well positioned to deliver accelerated growth in the second half of the year and beyond."

Company Strategy